These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32227432)

  • 1. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
    Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
    Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
    Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
    Verma S; Leiter LA; Zinman B; Sharma A; Mattheus M; Fitchett D; George J; Ofstad AP; Kosiborod MN; Wanner C; Inzucchi SE
    ESC Heart Fail; 2021 Aug; 8(4):2603-2607. PubMed ID: 34132492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
    Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
    Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
    McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
    Fitchett D; Inzucchi SE; Wanner C; Mattheus M; George JT; Vedin O; Zinman B; Johansen OE
    Eur Heart J; 2020 Jan; 41(2):209-217. PubMed ID: 31504427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
    Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
    JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
    Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
    Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
    Fitchett D; Inzucchi SE; Zinman B; Wanner C; Schumacher M; Schmoor C; Ohneberg K; Ofstad AP; Salsali A; George JT; Hantel S; Bluhmki E; Lachin JM; Zannad F
    ESC Heart Fail; 2021 Dec; 8(6):4517-4527. PubMed ID: 34605192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
    Ji Q; Ji L; Mu Y; Zhao J; Zinman B; Wanner C; George JT; Zwiener I; Ueki K; Yokote K; Ogawa W; Johansen OE
    Diabetes Obes Metab; 2021 Aug; 23(8):1886-1891. PubMed ID: 33950573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
    Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
    Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.